Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.

Autor: Tutaworn, Teerapat1,2, Nieves, Jeri W.1,3, Wang, Zhaorui4, Levin, Justin E.1, Yoo, Jae E.1, Lane, Joseph M.1,4,5 Lanej@hss.edu
Zdroj: Osteoporosis International. Mar2023, Vol. 34 Issue 3, p573-584. 12p. 1 Diagram, 4 Charts, 1 Graph.
Databáze: Academic Search Ultimate
Externí odkaz: